OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the presentation of eight real-world analyses supporting the effectiveness and ...

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...

Humira (adalimumab) and Entyvio (vedolizumab) are brand-name drugs. They’re both prescribed for Crohn’s disease and ulcerative colitis in certain people. This article explains the main similarities ...

The US Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of vedolizumab (Entyvio SC, Takeda) for maintenance therapy in adults with moderately to severely active ...

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...

− Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease − ...

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company ...